{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T03:55:04Z","timestamp":1785038104575,"version":"3.55.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Adoptive cell therapy has progressed rapidly following the success of CAR-T therapy, with NK cells emerging as strong candidates for next-generation treatments. NK cells naturally recognize abnormal cells without genetic modification and do not cause graft-versus-host disease, making them suitable for mass production from donor blood. Traditional NK cell expansion often relies on cancer-derived feeder cells, posing safety and quality concerns. This review examines both feeder cell-based and feeder-free NK cell culture methods. We analyze the limitations of feeder-based approaches and categorize feeder-free strategies, including cytokine combinations, antibody stimulation, blood components, nanoparticles, and hydrogels. Among these, nanoparticle-based methods show strong potential for enabling safe, scalable, and standardized NK cell expansion without the risks associated with feeder cells. In this paper, we review recent advancements in NK cell culture techniques and propose the potential of nanoparticle technology in developing feeder-free NK cell culture methods.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1675353","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:25:48Z","timestamp":1759123548000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Recent advances in feeder-free NK cell expansion as a future direction of adoptive cell therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Jimin","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munsik","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanbin","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilkoo","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeehun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01056-8","article-title":"Next generation of immune checkpoint inhibitors and beyond","volume":"14","author":"Marin-Acevedo","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2015.12.003","article-title":"Chemotherapy and immunotherapy: mapping the road ahead","volume":"39","author":"Cook","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","article-title":"CAR-T cell therapy: the efficacy and toxicity balance","volume":"18","author":"Chohan","year":"2023","journal-title":"Curr Hematol Malig Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115888","article-title":"The paths and challenges of \u201coff-the-shelf\u201d CAR-T cell therapy: An overview of clinical trials","volume":"169","author":"Moradi","year":"2023","journal-title":"BioMed Pharmacothe"},{"key":"B7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.46989\/001c.121404","article-title":"Allogeneic and other innovative chimeric antigen receptor platforms","volume":"6","author":"Jallouk","year":"2024","journal-title":"Clin Hematol Int"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016200","article-title":"Allogeneic natural killer cell therapy","volume":"141","author":"Berrien-Elliott","year":"2023","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40364-022-00364-6","article-title":"CAR-NK cells for cancer immunotherapy: from bench to bedside","volume":"10","author":"Zhang","year":"2022","journal-title":"biomark Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"14916","DOI":"10.1038\/s41598-019-51287-6","article-title":"Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells","volume":"9","author":"Ojo","year":"2019","journal-title":"Sci Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/iub.2898","article-title":"Enhancing the activation of T cells through anti-CD3\/CD28 magnetic beads by adjusting the antibody ratio","volume":"76","author":"Chen","year":"2024","journal-title":"IUBMB Life"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cells13050451","article-title":"Building a better defense: expanding and improving natural killer cells for adoptive cell therapy","volume":"13","author":"Maia","year":"2024","journal-title":"Cells"},{"key":"B13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-020-01014-w","article-title":"NK cell-based cancer immunotherapy: from basic biology to clinical development","volume":"14","author":"Liu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1089\/ten.TEB.2014.0547","article-title":"Feeder layer cell actions and applications","volume":"21","author":"Llames","year":"2015","journal-title":"Tissue Eng Part T Rev"},{"key":"B15","doi-asserted-by":"publisher","first-page":"11075","DOI":"10.1038\/s41598-017-09259-1","article-title":"Expansion of cytotoxic natural killer cells using irradiated autologous peripheral blood mononuclear cells and anti-CD16 antibody","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00854","article-title":"Influence of irradiated peripheral blood mononuclear cells on both ex vivo proliferation of human natural killer cells and change in cellular property","volume":"8","author":"Delso-Vallejo","year":"2017","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040811","article-title":"Directed differentiation of mobilized hematopoietic stem and progenitor cells into functional NK cells with enhanced antitumor activity","volume":"9","author":"Oberoi","year":"2020","journal-title":"Cells (Basel)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00879","article-title":"Expansion of human NK cells using K562 cells expressing OX40 ligand and short exposure to IL-21","volume":"10","author":"Kweon","year":"2019","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02982-9","article-title":"Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21","volume":"71","author":"Thangaraj","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.22809","article-title":"Effect of IL-18 on the expansion and phenotype of human natural killer cells: application to cancer immunotherapy","volume":"14","author":"Senju","year":"2018","journal-title":"Int J Biol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169426","article-title":"Selective expansion of NKG2C+ adaptive NK cells using K562 cells expressing HLA-E","volume":"23","author":"Phan","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16010133","article-title":"Obtaining gene-modified HLA-E-expressing feeder cells for stimulation of natural killer cells","volume":"16","author":"Alekseeva","year":"2024","journal-title":"Pharmaceutics"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2022.42.6.638","article-title":"Natural killer cell expansion and cytotoxicity differ depending on the culture medium used","volume":"42","author":"Koh","year":"2022","journal-title":"Ann Lab Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2020.02.004","article-title":"Artificial feeder cells expressing ligands for killer cell immunoglobulin-like receptors and CD94\/NKG2A for expansion of functional primary natural killer cells with tolerance to self","volume":"22","author":"Michen","year":"2020","journal-title":"Cytotherapy"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/14653240902807034","article-title":"Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells","volume":"11","author":"Berg","year":"2009","journal-title":"Cytotherapy"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2015.03.611","article-title":"Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy","volume":"17","author":"Granzin","year":"2015","journal-title":"Cytotherapy"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00759-9","article-title":"Harnessing novel engineered feeder cells expressing activating molecules for optimal expansion of NK cells with potent antitumor activity","volume":"19","author":"Min","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00676","article-title":"A two-phase expansion protocol combining interleukin (IL)-15 and IL-21 improves natural killer cell proliferation and cytotoxicity against rhabdomyosarcoma","volume":"8","author":"Wagner","year":"2017","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0652-7","article-title":"IL-27 enhances IL-15\/IL-18-mediated activation of human natural killer cells","volume":"7","author":"Choi","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/s0198-8859(01)00313-5","article-title":"A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells","volume":"62","author":"Carlens","year":"2001","journal-title":"Hum Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jcyt.2015.09.011","article-title":"Ex vivo expansion of natural killer cells from human peripheral blood mononuclear cells co-stimulated with anti-CD3 and anti-CD52 monoclonal antibodies","volume":"18","author":"Masuyama","year":"2016","journal-title":"Cytotherapy"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225866","article-title":"Anti-tumor activity of expanded PBMC-derived NK cells by feeder-free protocol in ovarian cancer","volume":"13","author":"Chen","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"9493","DOI":"10.1038\/s41598-023-36200-6","article-title":"Comparison of the different anti-CD16 antibody clones in the activation and expansion of peripheral blood NK cells","volume":"13","author":"Kim","year":"2023","journal-title":"Sci Rep"},{"key":"B34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.reth.2023.05.006","article-title":"An efficient feeder-free and chemically-defined expansion strategy for highly purified natural killer cells derived from human cord blood","volume":"24","author":"Nakazawa","year":"2023","journal-title":"Regener Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e0212455","DOI":"10.1371\/journal.pone.0212455","article-title":"Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro","volume":"14","author":"Tanaka","year":"2019","journal-title":"PloS One"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/lifemedi\/lnad011","article-title":"Human platelet lysate as a substitute for serum in natural killer cell generation and expansion","volume":"2","author":"Li","year":"2023","journal-title":"Life Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.803380","article-title":"Feeder-cell-free and serum-free expansion of natural killer cells using Cloudz microspheres, G-Rex6M, and human platelet lysate","volume":"13","author":"Johnson","year":"2022","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1159","article-title":"Cell-specific targeting of nanoparticles by multivalent attachment of small molecules","volume":"23","author":"Weissleder","year":"2005","journal-title":"Nat Biotechnol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.2c08360","article-title":"Cellular nanodiscs made from bacterial outer membrane as a platform for antibacterial vaccination","volume":"17","author":"Noh","year":"2023","journal-title":"ACS Nano"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202202603","article-title":"In situ activated NK cell as bio-orthogonal targeted live-cell nanocarrier augmented solid tumor immunotherapy","volume":"32","author":"Meng","year":"2022","journal-title":"Adv Funct Mater"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e1706759","DOI":"10.1002\/adma.201706759","article-title":"Cell membrane coating nanotechnology","volume":"30","author":"Fang","year":"2018","journal-title":"Adv Mater"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.3c01775","article-title":"Cancer cell membrane nanodiscs for antitumor vaccination","volume":"23","author":"Guo","year":"2023","journal-title":"Nano Lett"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2019.119418","article-title":"Multifunctional nanoparticles for genetic engineering and bioimaging of natural killer (NK) cell therapeutics","volume":"221","author":"Kim","year":"2019","journal-title":"Biomaterials"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.12.037","article-title":"Generation of highly cytotoxic natural killer cells for treatment of acute myelogenous leukemia using a feeder-free, particle-based approach","volume":"21","author":"Oyer","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2020.102333","article-title":"Cell membrane-encapsulated magnetic nanoparticles for enhancing natural killer cell-mediated cancer immunotherapy","volume":"32","author":"Wu","year":"2021","journal-title":"Nanomedicine"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00763-8","article-title":"The roles of extracellular vesicles in the immune system","volume":"23","author":"Buzas","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e4942","DOI":"10.1371\/journal.pone.0004942","article-title":"Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha","volume":"4","author":"Viaud","year":"2009","journal-title":"PloS One"},{"key":"B49","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40824-023-00403-9","article-title":"NK cells encapsulated in micro\/macropore-forming hydrogels via 3D bioprinting for tumor immunotherapy","volume":"27","author":"Kim","year":"2023","journal-title":"Biomater Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.9b12816","article-title":"NK-cell-encapsulated porous microspheres via microfluidic electrospray for tumor immunotherapy","volume":"11","author":"Wu","year":"2019","journal-title":"ACS Appl Mater Interf"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114665","article-title":"Engineered cell-based therapies in ex vivo ready-made CellDex capsules have therapeutic efficacy in solid tumors","volume":"162","author":"Van Schaik","year":"2023","journal-title":"BioMed Pharmacothe"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1675353\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:25:49Z","timestamp":1759123549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1675353\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":51,"alternative-id":["10.3389\/fimmu.2025.1675353"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1675353","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"article-number":"1675353"}}